Ke Geng

Partner

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

pdf

Ke Geng, managing partner of the Beijing office, advises Chinese companies in connection with outbound investments and exchange listings in the United States or Hong Kong, as well as the privatization of US or HK listed companies, private equity and venture capital financing, mergers and acquisitions transactions, and general corporate matters. Ke provides client-oriented, proactive, and cost-effective services to companies spanning a wide variety of industries, including healthcare, technology, media, and telecommunications (TMT).

Prior to joining O’Melveny, Ke practiced at another large international law firm.

Languages

  • Mandarin Chinese

Honors & Awards

  • Recognized by IFLR1000 as a “Notable Practitioner” in the practice area of Mergers & Acquisitions (China) (2019 & 2020)

Admissions

Bar Admissions

  • New York

Education

  • Northwestern University School of Law, J.D., 2003 
  • New York University, Ph.D., Biochemistry, 2001
  • Peking University, B.S., 1994

Professional Activities

Publications

  • “Accessing Capital Through Customised PIPE Offerings,” Eurekahedge e-newsletter (November 15, 2016)
  • “Should China Provide Intellectual Property Protection for Genetically Modified Animals?” Northwestern Journal of International Law and Business (Winter 2003) 

Offshore Public Offerings

  • Represented Viva Biotech (1873.HK) in its HK$1,521.5 million (approximately US$194 million) IPO on the Main Board of the Hong Kong Stock Exchange
  • Represented Dexin China Holdings Company Limited (2019.HK) in its US$190 million IPO on the Main Board of the Hong Kong Stock Exchange
  • Represented Bank of Qingdao (03866.HK) in its US$531 million IPO and listing on the Hong Kong Stock Exchange
  • Represented Shanghai Haohai Biological (6826.HK) in its US$300 million IPO and listing on the Hong Kong Stock Exchange
  • Represented Credit Suisse and China Renaissance as joint bookrunners in the US$53 million initial public offering and NYSE listing of ADS of Jupai Holdings Limited (NYSE: JP)
  • Represented eHi Car Services (NYSE: EHIC) in its US$120 million IPO and listing on the NYSE 
  • Represented Phoenix Healthcare (01515.HK) in its US$220 million IPO and listing on the Hong Kong Stock Exchange 
  • Represented Credit Suisse and an American multinational banking and financial services holding company as joint bookrunners in the US$110 million IPO and listing on the NYSE of Leju Holdings Ltd. (NYSE: LEJU)
  • Represented Credit Suisse and Goldman Sachs as joint bookrunners in US$138 million IPO of Tarena Technologies Inc. (NASDAQ:TEDU) on the NASDAQ 
  • Represented Morgan Stanley, Credit Suisse and Citigroup as lead underwriters on the US$215 million US IPO of 58.com (NYSE: WUBA) 
  • Represented Hengxing Gold (2303:HK) in its HK$330.4 million (approximately US$47 million) IPO and listing on the Hong Kong Stock Exchange 
  • Represented Montage (NASDAQ: MONT) in its US$70 million IPO and listing on NASDAQ 
  • Represented China Polymetallic Mining Limited (2133.HK) in its US$1.82 billion IPO and listing on the Hong Kong Stock Exchange
  • Represented a leading Chinese Internet television company in its US$233 million IPO and listing on the NYSE 
  • Represented a leading Chinese social network website in its US$743 million IPO and listing on the NYSE 
  • Represented one of the largest contract research organizations in China in its US$87 million IPO and listing on the NYSE 
  • Represented a provider of real estate information and consulting services in its US$248 million IPO and listing on NASDAQ 
  • Represented a leading Fujian-based property developer in its US$210 million IPO and listing on the Hong Kong Stock Exchange 
  • Represented the underwriters of a US$212 million IPO and listing on the NYSE of a leading contract research organization in China 
  • Represented a major Chinese bank in its US$5.4 billion IPO and listing on Hong Kong Stock Exchange and Shanghai Stock Exchange 
  • Represented a major Chinese bank in its US$9.2 billion IPO and listing on Hong Kong Stock Exchange and Shanghai Stock Exchange 
  • Represented a biopharmaceutical company in its IPO and listing on NASDAQ 
  • Represented the underwriters in the IPO of a New York-based real estate investment company 
  • Represented a real estate finance group in its IPO and subsequent debt offering
  • Represented the underwriters in the 144A/Regulation S offering of a New York-based specialty finance company that invests in real estate-related securities and other asset classes
VIEW MORE

Press Releases

O’Melveny Represents Consortium in Going Private Transaction of SORL Auto Parts

December 2, 2019

O'Melveny Represents Essence International in Highpower's Going-Private Transaction

November 11, 2019

O’Melveny Represents Shanghai Kindly Medical Instruments in US$106 Million Hong Kong IPO

November 8, 2019

O'Melveny Represents Aesthetic Medical International Holdings in its Nasdaq IPO

October 26, 2019

O’Melveny Represents Viva Biotech in its US$194 Million Hong Kong IPO

May 9, 2019

O’Melveny Represents Tiger Brokers in Nasdaq IPO

March 21, 2019

O’Melveny Represents Property Developer Dexin China in its US$190 Million Hong Kong IPO

February 26, 2019

O’Melveny Represents Underwriters in US$133 Million Hong Kong IPO of FingerTango

July 17, 2018

O’Melveny Represents Placement Agents in Issuance of H-Shares of Sinopec Oilfield Service Corporation

February 13, 2018

O’Melveny Represents China Securities in Digital Hollywood Interactive IPO

December 15, 2017

In the News

Alerts and Publications